Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
ZEGFROVY (SUNVOZERTINIB) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
ZEGFROVY
NDA
Get alerts
SUNVOZERTINIB | N219839 | DIZAL (JIANGSU) PHARMACEUTICAL CO LTD
2 strengths
3 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
3 unique patents, 1 exclusivity by expiration date
All strengths
150MG
200MG
Active (3)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
Today
11007198
Jan. 28, 2039
11504375
Jan. 28, 2039
11896597
Jan. 28, 2039
NCE
Jul. 2, 2030
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 150MG
RLD
3 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Jul 2, 2025
Patents (3)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
11007198
Jan 28, 2039
—
Yes
Yes
—
—
11504375
Jan 28, 2039
—
Yes
Yes
U-3220
TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
—
11896597
Jan 28, 2039
—
Yes
Yes
U-3220
TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
—
Exclusivities (1)
Code
Date
Status
NCE
Jul 2, 2030
Active
#002 — 200MG
RLD
3 patents
1 exclusivity
▾
TABLET;ORAL | Approved: Jul 2, 2025